AUTL:NSD-Autolus Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.6

Change

-0.03 (-0.83)%

Market Cap

USD 0.96B

Volume

0.94M

Analyst Target

USD 26.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.68 (+1.01%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-4.33 (-0.41%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

+1.03 (+0.37%)

USD 35.31B
ARGX argenx NV ADR

+5.20 (+0.96%)

USD 32.41B
MRNA Moderna Inc

-2.90 (-4.34%)

USD 25.27B
BGNE BeiGene Ltd

+6.47 (+2.88%)

USD 24.38B
RPRX Royalty Pharma Plc

+0.09 (+0.32%)

USD 16.72B
UTHR United Therapeutics Corporatio..

-0.52 (-0.15%)

USD 15.95B
SMMT Summit Therapeutics PLC

-1.80 (-8.22%)

USD 15.35B
PCVX Vaxcyte Inc

+1.27 (+1.11%)

USD 14.00B

ETFs Containing AUTL

HOML 8.77 % 0.00 %

N/A

N/A
CLAW 6.09 % 0.95 %

N/A

N/A
ITB 4.25 % 0.42 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 2.15 % 0.35 %

-0.27 (-0.43%)

N/A
VAMO 1.76 % 0.64 %

N/A

N/A
ZEUS:CA 1.40 % 0.73 %

N/A

N/A
EZM WisdomTree U.S. MidCap Ea.. 1.20 % 0.38 %

-0.65 (-0.43%)

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.04 % 0.15 %

-0.60 (-0.43%)

N/A
ONEO SPDR® Russell 1000 Momen.. 0.57 % 0.20 %

-0.60 (-0.43%)

N/A
WDSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

-1.49 (-0.43%)

N/A
WOSC:LSE SPDR MSCI World Small Cap.. 0.21 % 0.00 %

+0.26 (+-0.43%)

N/A
WLDS:LSE iShares MSCI World Small .. 0.19 % 0.00 %

-0.01 (-0.43%)

N/A
WSML:LSE iShares MSCI World Small .. 0.19 % 0.00 %

-0.09 (-0.43%)

N/A
IUSN:F iShares MSCI World Small .. 0.19 % 0.00 %

-0.03 (-0.43%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.10% 32% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.10% 32% F 19% F
Trailing 12 Months  
Capital Gain 69.01% 80% B- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.01% 80% B- 88% B+
Trailing 5 Years  
Capital Gain -70.61% 46% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.61% 46% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -1.29% N/A N/A 40% F
Dividend Return -1.29% N/A N/A 36% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.88% N/A N/A 22% F
Risk Adjusted Return -1.63% N/A N/A 38% F
Market Capitalization 0.96B 80% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector